Jamie E Chaft Selected Research

Angiogenesis Inhibitors

1/2017

The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jamie E Chaft Research Topics

Disease

40	Neoplasms (Cancer) 10/2022 - 05/2011
37	Lung Neoplasms (Lung Cancer) 01/2022 - 10/2011
29	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 05/2011
12	Adenocarcinoma of Lung 01/2021 - 09/2012
7	Neoplasm Metastasis (Metastasis) 11/2021 - 02/2014
4	Disease Progression 01/2020 - 10/2011
4	Adenocarcinoma 01/2019 - 02/2012
3	Residual Neoplasm 01/2020 - 12/2017
2	Radiation Pneumonitis 01/2021 - 01/2020
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2019 - 04/2016
2	Brain Neoplasms (Brain Tumor) 11/2018 - 10/2018
2	Fatigue 10/2018 - 07/2018
2	Pneumonia (Pneumonitis) 07/2018 - 03/2017
1	Human Influenza (Influenza) 01/2021
1	Dyspnea (Shortness of Breath) 10/2018
1	Esophagitis 07/2018
1	Dermatitis 07/2018
1	Body Weight (Weight, Body) 05/2018
1	Myasthenia Gravis 03/2016
1	Pericardial Effusion 03/2016
1	Colitis 03/2016
1	Bullous Pemphigoid (Pemphigoid) 01/2016
1	Breast Neoplasms (Breast Cancer) 02/2014
1	Hemoptysis 08/2013
1	Carcinoma (Carcinomatosis) 09/2012
1	Thymoma (Thymic Carcinoma) 02/2012
1	Sarcoma (Soft Tissue Sarcoma) 02/2012
1	Neuroblastoma 02/2012
1	Carcinogenesis 02/2012
1	Bronchiolo-Alveolar Adenocarcinoma (Adenocarcinoma, Bronchiolo Alveolar) 05/2011

Drug/Important Bio-Agent (IBA)

11	ErbB Receptors (EGF Receptor)IBA 01/2021 - 05/2011
9	durvalumabIBA 01/2022 - 03/2016
8	Immune Checkpoint InhibitorsIBA 10/2022 - 01/2018
8	B7-H1 AntigenIBA 01/2022 - 03/2017
7	Tyrosine Kinase InhibitorsIBA 11/2021 - 10/2011
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2014
5	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2020 - 10/2011
5	Proteins (Proteins, Gene)FDA Link 05/2018 - 05/2011
4	Circulating Tumor DNAIBA 12/2020 - 12/2017
4	Monoclonal AntibodiesIBA 02/2018 - 01/2016
3	osimertinibIBA 01/2022 - 01/2020
3	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 10/2013
3	Bevacizumab (Avastin)FDA Link 01/2020 - 08/2013
3	LigandsIBA 02/2018 - 08/2017
3	human ERBB2 proteinIBA 03/2016 - 02/2012
3	Gefitinib (Iressa)FDA Link 12/2012 - 05/2011
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2020
2	PlatinumIBA 01/2021 - 01/2019
2	AfatinibIBA 01/2021 - 12/2015
2	cyclo(Arg-Pro) (CI 4)IBA 01/2021 - 01/2020
2	tremelimumabIBA 12/2020 - 03/2016
2	NivolumabIBA 01/2020 - 05/2018
2	Pharmaceutical PreparationsIBA 12/2018 - 07/2018
2	atezolizumabIBA 11/2018 - 08/2017
2	Pemetrexed (MTA)FDA Link 01/2017 - 04/2016
2	Docetaxel (Taxotere)FDA Link 04/2016 - 10/2013
2	Vinorelbine (Navelbine)FDA LinkGeneric 04/2016 - 10/2013
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2015 - 09/2012
1	Interleukin-7 (Interleukin 7)IBA 01/2021
1	IpilimumabIBA 01/2020
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020
1	Therapeutic UsesIBA 01/2019
1	A-factor (Streptomyces)IBA 01/2019
1	SteroidsIBA 10/2018
1	Prednisone (Sone)FDA LinkGeneric 10/2018
1	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2018
1	AntibodiesIBA 05/2018
1	Thyroid Nuclear Factor 1IBA 01/2017
1	Angiogenesis InhibitorsIBA 01/2017
1	Carboplatin (JM8)FDA LinkGeneric 04/2016
1	Gemcitabine FDA Link 04/2016
1	Lipase (Acid Lipase)FDA Link 03/2016
1	Complement System Proteins (Complement)IBA 01/2016
1	AutoantibodiesIBA 01/2016
1	Epidermal Growth Factor (EGF)IBA 12/2015
1	VaccinesIBA 11/2014
1	NeuroserpinIBA 02/2014
1	SerpinsIBA 02/2014
1	Plasminogen Activator Inhibitor 2IBA 02/2014
1	Plasminogen Activators (Plasminogen Activator)IBA 02/2014
1	Neural Cell Adhesion Molecule L1 (L1 Cell Adhesion Molecule)IBA 02/2014
1	Fibrinolysin FDA Link 02/2014
1	Isoflurophate (DFP)FDA Link 09/2012
1	MAP Kinase Kinase 1IBA 02/2012
1	Anaplastic Lymphoma KinaseIBA 02/2012

Therapy/Procedure

34	Therapeutics 01/2022 - 10/2011
17	Drug Therapy (Chemotherapy) 01/2022 - 10/2011
13	Immunotherapy 01/2022 - 01/2014
8	Adjuvant Chemotherapy 01/2022 - 08/2013
8	Neoadjuvant Therapy 01/2020 - 09/2012
6	Radiotherapy 01/2022 - 01/2017
3	Aftercare (After-Treatment) 01/2020 - 09/2017
2	Precision Medicine 12/2017 - 01/2014
1	Fecal Microbiota Transplantation 10/2022
1	Chemoradiotherapy 01/2021
1	Adrenalectomy 01/2019
1	Metastasectomy 01/2019
1	Retreatment 01/2018
1	Investigational Therapies (Experimental Therapy) 09/2012